OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency August 29, 2019 - NASDAQ Companies 0 » View More News for August 29, 2019
